Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses the FDA approval of of ibrutinib (Imbruvica) as a treatment for patients with marginal zone lymphoma (MZL).
Allison C. Rosenthal, DO
Advertisement
Articles by Allison C. Rosenthal, DO
Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses some of the treatment strategies for patients with indolent lymphomas.
Advertisement
Latest Updated Articles
Dr. Rosenthal on Treatment Strategies for Indolent LymphomasOctober 20th 2016
Dr. Rosenthal on FDA Approval of Ibrutinib in Marginal Zone LymphomaJanuary 19th 2017
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
5